Detalhe da pesquisa
1.
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med
; 374(4): 311-22, 2016 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26639348
2.
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Lancet Oncol
; 18(2): 230-240, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28089635
3.
Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
Oncologist
; 22(11): 1283-1291, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28851760
4.
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Lancet Oncol
; 17(6): 768-778, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27178240
5.
Promoting Research, Awareness, and Discussion on AI in Medicine Using #MedTwitterAI: A Longitudinal Twitter Hashtag Analysis.
Front Public Health
; 10: 856571, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35844878
6.
Pharmacologic modulation of parasympathetic activity in heart failure.
Heart Fail Rev
; 16(2): 179-93, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20924667
7.
Online information discrepancies regarding safety of medicine use during pregnancy and lactation: an IMI ConcePTION study.
Expert Opin Drug Saf
; 20(9): 1117-1124, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34080506
8.
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
Clin Cancer Res
; 24(18): 4371-4379, 2018 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29895707
9.
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
J Clin Oncol
; 36(19): 1973-1980, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29715056
10.
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
J Clin Oncol
; 35(8): 826-833, 2017 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28095146